# GCK

## Overview
The GCK gene encodes the enzyme glucokinase, a member of the hexokinase family, which plays a critical role in glucose metabolism. Glucokinase is primarily expressed in pancreatic β-cells and liver hepatocytes, where it functions as a glucose sensor and regulator of insulin secretion and glycogen synthesis, respectively. Unlike other hexokinases, glucokinase exhibits a unique sigmoidal kinetic response to glucose and is not inhibited by its product, glucose-6-phosphate, allowing it to effectively modulate glucose homeostasis (Sternisha2019Molecular; Iynedjian1993Mammalian). The enzyme's activity is regulated through interactions with various proteins, such as the glucokinase regulatory protein (GKRP), and is subject to post-translational modifications that influence its conformation and function (Beck2013Structural; Sternisha2019Molecular). Mutations in the GCK gene are linked to several metabolic disorders, including maturity-onset diabetes of the young type 2 (MODY2), permanent neonatal diabetes mellitus (PNDM), and hyperinsulinemic hypoglycemia (Osbak2009Update; Gloyn2003Glucokinase).

## Structure
The human glucokinase (GCK) protein is a monomeric enzyme composed of 465 amino acid residues. It features a prototypic hexokinase fold, consisting of a large and a small domain separated by a variable opening angle (Larion2012Order–Disorder). The active site, where glucose binds, is located between these two domains (Gersing2024Characterizing). In its unliganded state, GCK adopts a 'super-open' conformation with a large interdomain angle and a disordered active-site loop (residues 150-179) (Sternisha2020Nanosecond-Timescale). Upon glucose binding, the enzyme transitions to a closed conformation, characterized by a smaller interdomain angle and a β-hairpin formation in the active-site loop, which is essential for catalytic activity (Gersing2024Characterizing).

GCK's structure is dynamic, with conformational changes occurring on a millisecond timescale, which is comparable to its catalytic rate (Gersing2024Characterizing). Post-translational modifications such as S-nitrosylation and SUMOylation influence its conformational states and activity, with S-nitrosylation promoting the closed conformation and SUMOylation enhancing catalytic activity (Sternisha2019Molecular). The enzyme's interaction with glucokinase regulatory protein (GKRP) involves a large buried surface area, with specific residues crucial for binding (Beck2013Structural).

## Function
Glucokinase (GCK) is a monomeric enzyme that plays a pivotal role in glucose metabolism, primarily in pancreatic β-cells and liver hepatocytes. In pancreatic β-cells, GCK functions as a glucose sensor, regulating insulin secretion in response to blood glucose levels. It catalyzes the ATP-dependent conversion of glucose to glucose-6-phosphate, the first and rate-limiting step of glycolysis, which is crucial for the insulinotropic effect. This process involves the generation of ATP, which inhibits ATP-sensitive K+ channels, leading to membrane depolarization and calcium influx, ultimately triggering insulin secretion (Sternisha2019Molecular; Iynedjian1993Mammalian).

In the liver, GCK facilitates glucose uptake and conversion to glucose-6-phosphate, influencing glycogen synthesis and glycolysis. It is involved in metabolic zonation, being more concentrated in perivenous hepatocytes, which allows for efficient glycogen synthesis from glucose (Iynedjian1993Mammalian). GCK's unique sigmoidal kinetic response to glucose allows it to alter the threshold for glucose-stimulated insulin secretion, and unlike other hexokinases, it is not inhibited by physiological concentrations of its product, glucose-6-phosphate (Sternisha2019Molecular). This enzyme's activity is crucial for maintaining glucose homeostasis, and its deficiency can lead to forms of diabetes mellitus (Matschinsky1990Glucokinase).

## Clinical Significance
Mutations in the GCK gene, which encodes glucokinase, are associated with several glucose metabolism disorders. Heterozygous inactivating mutations in GCK lead to maturity-onset diabetes of the young type 2 (MODY2), characterized by mild fasting hyperglycemia present from birth. This condition is often detected later in life and is associated with a low risk of microvascular complications, typically not requiring insulin or oral hypoglycemic agents for management (Osbak2009Update). 

Homozygous inactivating mutations result in permanent neonatal diabetes mellitus (PNDM), a severe condition presenting at birth. PNDM is rare, with only a few cases reported, often in consanguineous families (Osbak2009Update; Gloyn2003Glucokinase). 

Activating mutations in GCK cause hyperinsulinemic hypoglycemia (GCK-HH), characterized by inappropriate insulin secretion despite hypoglycemia. These mutations increase glucokinase's affinity for glucose, leading to excessive insulin secretion at low blood glucose levels. GCK-HH is generally responsive to diazoxide treatment, and unlike other forms of hyperinsulinemic hypoglycemia, it does not typically lead to type 2 diabetes mellitus later in life (Osbak2009Update). 

The GCK gene's mutations are distributed throughout its exons, with no specific mutation hotspots, and most mutations are private, though some have been reported in multiple families (Gloyn2003Glucokinase).

## Interactions
Glucokinase (GCK) participates in several significant protein-protein interactions that regulate its activity and localization. In the liver, GCK interacts with the glucokinase regulatory protein (GKRP), which binds to the inactive, super-open conformation of GCK. This interaction sequesters GCK in the nucleus and inhibits its activity, a process modulated by fructose phosphates and acetylation of GKRP (Sternisha2019Molecular; Iynedjian2008Molecular). The GCK-GKRP complex is characterized by a large buried surface area and involves hydrophobic and coulombic interactions, with specific residues in GCK crucial for binding (Beck2013Structural).

GCK also interacts with phosphofructokinase-2/fructose bisphosphatase-2 (PFK-2/FBPase-2) in liver hepatocytes and pancreatic β-cells. This interaction modestly enhances GCK's Vmax and stabilizes it against oxidative damage, with colocalization observed in the cytoplasm under high glucose conditions (Sternisha2019Molecular).

In pancreatic cells, GCK is associated with insulin secretory granules, potentially involving interactions with nitric oxide synthase (NOS) and S-nitrosylation, which influence its localization and activity (Sternisha2019Molecular). GCK also forms part of a mitochondrial-associated complex with the BCL 2-associated death promoter (BAD), linking glycolysis and apoptosis (Sternisha2019Molecular). These interactions highlight the complex regulatory network governing GCK's role in glucose metabolism.


## References


[1. (Beck2013Structural) Tobias Beck and Brian G. Miller. Structural basis for regulation of human glucokinase by glucokinase regulatory protein. Biochemistry, 52(36):6232–6239, August 2013. URL: http://dx.doi.org/10.1021/bi400838t, doi:10.1021/bi400838t. This article has 57 citations and is from a peer-reviewed journal.](https://doi.org/10.1021/bi400838t)

[2. (Osbak2009Update) Kara K. Osbak, Kevin Colclough, Cecile Saint-Martin, Nicola L. Beer, Christine Bellanné-Chantelot, Sian Ellard, and Anna L. Gloyn. Update on mutations in glucokinase (gck), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Human Mutation, 30(11):1512–1526, November 2009. URL: http://dx.doi.org/10.1002/humu.21110, doi:10.1002/humu.21110. This article has 369 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.21110)

[3. (Iynedjian2008Molecular) P. B. Iynedjian. Molecular physiology of mammalian glucokinase. Cellular and Molecular Life Sciences, August 2008. URL: http://dx.doi.org/10.1007/s00018-008-8322-9, doi:10.1007/s00018-008-8322-9. This article has 269 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s00018-008-8322-9)

[4. (Sternisha2019Molecular) Shawn M. Sternisha and Brian G. Miller. Molecular and cellular regulation of human glucokinase. Archives of Biochemistry and Biophysics, 663:199–213, March 2019. URL: http://dx.doi.org/10.1016/j.abb.2019.01.011, doi:10.1016/j.abb.2019.01.011. This article has 117 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.abb.2019.01.011)

[5. (Matschinsky1990Glucokinase) Franz M Matschinsky. Glucokinase as glucose sensor and metabolic signal generator in pancreatic β-cells and hepatocytes. Diabetes, 39(6):647–652, June 1990. URL: http://dx.doi.org/10.2337/diab.39.6.647, doi:10.2337/diab.39.6.647. This article has 361 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.2337/diab.39.6.647)

[6. (Gersing2024Characterizing) Sarah Gersing, Thea K. Schulze, Matteo Cagiada, Amelie Stein, Frederick P. Roth, Kresten Lindorff-Larsen, and Rasmus Hartmann-Petersen. Characterizing glucokinase variant mechanisms using a multiplexed abundance assay. Genome Biology, April 2024. URL: http://dx.doi.org/10.1186/s13059-024-03238-2, doi:10.1186/s13059-024-03238-2. This article has 2 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1186/s13059-024-03238-2)

[7. (Iynedjian1993Mammalian) P B Iynedjian. Mammalian glucokinase and its gene. Biochemical Journal, 293(1):1–13, July 1993. URL: http://dx.doi.org/10.1042/bj2930001, doi:10.1042/bj2930001. This article has 233 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1042/bj2930001)

[8. (Larion2012Order–Disorder) Mioara Larion, Roberto Kopke Salinas, Lei Bruschweiler-Li, Brian G. Miller, and Rafael Brüschweiler. Order–disorder transitions govern kinetic cooperativity and allostery of monomeric human glucokinase. PLoS Biology, 10(12):e1001452, December 2012. URL: http://dx.doi.org/10.1371/journal.pbio.1001452, doi:10.1371/journal.pbio.1001452. This article has 52 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1371/journal.pbio.1001452)

[9. (Gloyn2003Glucokinase) Anna L. Gloyn. Glucokinase (gck) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy. Human Mutation, 22(5):353–362, November 2003. URL: http://dx.doi.org/10.1002/humu.10277, doi:10.1002/humu.10277. This article has 210 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.10277)

[10. (Sternisha2020Nanosecond-Timescale) Shawn M. Sternisha, A. Carl Whittington, Juliana A. Martinez Fiesco, Carol Porter, Malcolm M. McCray, Timothy Logan, Cristina Olivieri, Gianluigi Veglia, Peter J. Steinbach, and Brian G. Miller. Nanosecond-timescale dynamics and conformational heterogeneity in human gck regulation and disease. Biophysical Journal, 118(5):1109–1118, March 2020. URL: http://dx.doi.org/10.1016/j.bpj.2019.12.036, doi:10.1016/j.bpj.2019.12.036. This article has 8 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.bpj.2019.12.036)